Tasly announced that in the first half of 2026, it will achieve total operating revenue of 4.201 billion yuan, a year-on-year decrease of 2.03%; net profit to mother of 893 million yuan, an increase of 15.23%; after deducting non-net profit of 871 million yuan, an increase of 36.01% over the previous year. Net profit returned to mother for the same period last year was 775 million yuan. The change in performance was mainly due to the decline in the traditional Chinese medicine injection industry and the decline in sales revenue for cold and fever medicines.

Tasly announced that in the first half of 2026, it will achieve total operating revenue of 4.201 billion yuan, a year-on-year decrease of 2.03%; net profit to mother of 893 million yuan, an increase of 15.23%; after deducting non-net profit of 871 million yuan, an increase of 36.01% over the previous year. Net profit returned to mother for the same period last year was 775 million yuan. The change in performance was mainly due to the decline in the traditional Chinese medicine injection industry and the decline in sales revenue for cold and fever medicines.